Abstracts tagged "gout"

Abstract Number: L05 • ACR Convergence 2024
Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels
Christian Schwabe¹, Orit Cohen Barak², Alexandra Cole³, Hadar Reuveni², Liron Shelev², Liora Blinder-Haddad² and Nicola Dalbeth⁴, ¹NZCR, Auckland, New Zealand, ²Protalix Ltd, Karmiel, Israel, ³NZCR, Christchurch, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
Abstract Number: 0274 • ACR Convergence 2024
Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout
Yana Pryymachenko¹, Ross Wilson¹, Haxby Abbott¹, Nicola Dalbeth² and Lisa Stamp³, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: To investigate the cost-effectiveness of low-dose colchicine prophylaxis for reducing gout flares when starting allopurinol using the “start-low go-slow” approach.Methods: This was a pre-planned…
Abstract Number: 1071 • ACR Convergence 2024
Rapid Access Microscopy and Real Time Case Discussion via a Secure Messaging App Improves Diagnostic Accuracy and Management of Acute Hot Swollen Joints
Anouchka Lewis¹, John Stack², Oisin Corish², Callum Swift², Tomás Breslin², Frank Lyons², Eavan Muldoon², Cian McDermott², Sharon Cowley², Helina Alemayehu², Oliver Boughton², Khaled Taha² and Geraldine McCarthy², ¹The Mater Misericordiae University Hospital, Dublin, Ireland, ²Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with acute swollen joints are often presumed to have septic arthritis, leading to treatment with intravenous antibiotics and arthroscopic washout. Previously at our…
Abstract Number: 1099 • ACR Convergence 2024
Distinct Metabolomic Signatures of Insulinemia and Incident Gout Risk: A Prospective Cohort Study Among Women
Sharan Rai¹, Hyon K. Choi², Chio Yokose¹ and Natalie McCormick¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and the metabolic syndrome frequently coexist. Intravenous insulin has been shown to raise serum urate levels in physiologic studies, and a Mendelian Randomization…
Abstract Number: 2006 • ACR Convergence 2024
Gout Flares After Stopping Anti-inflammatory Prophylaxis During the Early Phases of Urate-Lowering Therapy
Lisa Stamp¹, Chris Frampton¹, James O'Dell², Ted Mikuls², Jeff Newcomb² and Nicola Dalbeth³, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Nebraska Medical Center, Omaha, NE, ³University of Auckland, Auckland, New Zealand
Background/Purpose: Anti-inflammatory prophylaxis is recommended during the initial period of urate-lowering therapy (ULT) as gout flares are common during this time. The aim of this…
Abstract Number: 2022 • ACR Convergence 2024
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Sharan Rai¹, Gregory Challener¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…
Abstract Number: 0275 • ACR Convergence 2024
Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation
Sadiq Umar¹ and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago
Background/Purpose: Gout, the leading cause of inflammatory arthritis, is becoming increasingly prevalent worldwide, affecting both developed and developing countries. This condition results from the deposition…
Abstract Number: 1073 • ACR Convergence 2024
Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting
Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…
Abstract Number: 1100 • ACR Convergence 2024
Coronary Dual-Energy Computed Tomography for the Detection of Monosodium Urate Crystal Deposition in the Arteries of Individuals with and Without Gout (CORODECT): A Multi-Center Prospective Imaging Study
Chio Yokose¹, Tristan Pascart², Mangun Randhawa³, Padraic Kennedy⁴, Christoph Schwabl⁵, saiajay chigurupati³, Bohang Jiang³, Leo Lu⁶, Julia Held⁵, Gerlig Widmann⁵, F. Joseph Simeone³, Brian Ghoshhajra³, Adnan Sheikh⁴, Kamran Shojania⁴, Gudrun Feuchtner⁵, Andrea Klauser⁵, Savvas Nicolaou⁴, Jean-François Budzik², Fabio Becce⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Waltham, MA, ²Lille Catholic University, Lille, France, ³Massachusetts General Hospital, Boston, MA, ⁴Vancouver General Hospital, Vancouver, Canada, ⁵Medical University Innsbruck, Innsbruck, Austria, ⁶Arthritis Research Canada, Vancouver, BC, Canada, ⁷Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Prior dual-energy CT (DECT) studies have suggested that monosodium urate (MSU) crystals may be present in the coronary arteries of patients with gout. However,…
Abstract Number: 2007 • ACR Convergence 2024
Relationship Between Gout Flare Burden and Patient-Reported Outcome Following Allopurinol Initiation
Lisa Stamp¹, Chris Frampton¹, Sarah Stewart², Keith Petrie³, N Lawrence Edwards⁴, Angelo Gaffo⁵ and Nicola Dalbeth³, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²Auckland University of Technology, Auckland, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Florida, Florida, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout flares are the most important clinical feature for people who have the disease. Given currently available treatment possibilities and limitations, low disease activity…
Abstract Number: 2023 • ACR Convergence 2024
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
Frank Fan¹, Riyong Liu¹ and Yu Wang², ¹Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), ²Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)
Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
Abstract Number: 0277 • ACR Convergence 2024
Mesenchymal Stem Cells Derived from Human Bone Marrow Ameliorate Monosodium Urate Crystal-induced Inflammation
Jennifer Lee¹ and Ah Young Choi², ¹seoul st mary's hospital, Seoul, South Korea, ²The Cactholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Mesenchymal stem cells (MSCs) have anti-inflammatory properties and have been implicated in several inflammatory diseases. Acute gout is initiated by IL-1β produced by monosodium…
Abstract Number: 1083 • ACR Convergence 2024
Comparison of a Handheld Ultrasound Device with Cart-Based Ultrasound for the Assessment of Gout Lesions in People with Established Gout
Rachel Murdoch¹, Lene Terslev², Julia Martin³, Borislav Mihov¹, Gregory Gamble¹, Søren Torp-Pedersen⁴, Anne Horne¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Te Whatu Ora Te Toka Tumai, Auckland, New Zealand, ⁴Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Ultrasound is frequently used in rheumatology practice to assist with the diagnosis of rheumatic and musculoskeletal diseases. In patients with gout, it allows visualization…
Abstract Number: 1101 • ACR Convergence 2024
The Contemporary Prevalence of Comorbid Gout and Chronic Kidney Disease, Two Common Conditions with High Morbidity, in the US General Population
Chio Yokose¹, Leo Lu², Sharan Rai³, Natalie McCormick³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Waltham, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and chronic kidney disease (CKD) are both common conditions which are associated with high morbidity and mortality and often coexist. We sought to…
Abstract Number: 2008 • ACR Convergence 2024
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)
ullrich schwertschlag¹, william dongfang Shi², rOBERT PERRY³, Kwabena Ayesu⁴, rOY WU⁵, jerry liu⁶, JinSying Lin⁷ and Adam Jin⁸, ¹Atombio Science, PALO ALTO, CA, ²Jiangsu Atom Bioscience,, Suzhou, Jiangsu, China (People's Republic), ³Panax Clin Res, Miami Lakes, FL, ⁴OMEGARLLC, ORLANDO, FL, ⁵Atom Bioscience, SAN FRANCISCO, CA, ⁶atombio, San Diego, CA, ⁷Biostatconsulting, Wuzhong, Suzhou, Jiangsu, China (People's Republic), ⁸atom biosciences, Wuzhong, Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: In this open-label Phase 1 study, 22 participants were enrolled in 3 cohorts, 10 participants with normal kidney function (eGFR ≥90 ml/min/1.73m2 and no…

1
2
3
…
45
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].